Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
23.29
+0.45 (1.97%)
Nov 5, 2024, 4:00 PM EST - Market closed
Viridian Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Nov '24 Nov 5, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Market Capitalization | 1,778 | 1,145 | 1,176 | 429 | 64 | 15 | |
Market Cap Growth | -19.08% | -2.58% | 173.76% | 568.00% | 321.43% | -83.67% | |
Enterprise Value | 1,395 | 989 | 892 | 379 | 44 | -9 | |
Last Close Price | 22.84 | 21.78 | 29.21 | 19.77 | 16.45 | 7.20 | |
PE Ratio | - | -4.10 | -7.22 | -2.97 | -0.53 | -0.36 | |
PS Ratio | 2883.09 | 3647.53 | 663.46 | 144.94 | 61.23 | 3.42 | |
PB Ratio | 4.43 | 2.59 | 2.98 | 2.29 | 0.54 | 0.97 | |
P/FCF Ratio | -4.92 | -6.19 | -12.42 | -7.82 | -2.16 | -0.42 | |
P/OCF Ratio | -4.93 | -6.22 | -12.53 | -7.87 | -2.16 | -0.42 | |
EV/Sales Ratio | 4842.70 | 3150.76 | 503.65 | 127.79 | 41.48 | -2.10 | |
EV/EBITDA Ratio | -1.75 | -3.90 | -6.66 | -4.76 | -1.08 | 0.24 | |
EV/EBIT Ratio | -1.75 | -3.89 | -6.65 | -4.75 | -1.07 | 0.23 | |
EV/FCF Ratio | -2.60 | -5.35 | -9.43 | -6.89 | -1.46 | 0.26 | |
Debt / Equity Ratio | 0.04 | 0.05 | 0.01 | 0.00 | 0.00 | 0.53 | |
Debt / FCF Ratio | -0.13 | -0.12 | -0.06 | -0.01 | -0.02 | -0.23 | |
Asset Turnover | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 | 0.09 | |
Quick Ratio | 15.54 | 17.93 | 12.73 | 14.48 | 11.96 | 2.67 | |
Current Ratio | 15.82 | 18.26 | 12.93 | 14.68 | 12.14 | 2.92 | |
Return on Equity (ROE) | -53.97% | -56.80% | -44.57% | -51.61% | -163.07% | -124.81% | |
Return on Assets (ROA) | -33.45% | -34.37% | -26.28% | -29.75% | -31.36% | -51.84% | |
Return on Capital (ROIC) | -35.84% | -36.80% | -28.52% | -32.28% | -35.04% | -58.31% | |
Earnings Yield | -13.08% | -20.76% | -11.05% | -18.49% | -172.21% | -274.49% | |
FCF Yield | -9.68% | -16.16% | -8.05% | -12.79% | -46.39% | -236.90% | |
Buyback Yield / Dilution | -36.58% | -39.48% | -169.22% | -235.07% | -70.27% | -5.87% | |
Total Shareholder Return | -36.58% | -39.48% | -169.22% | -235.07% | -70.27% | -5.87% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.